Information Provided By: 
Fly News Breaks for October 31, 2016
OPXA
Oct 31, 2016 | 08:01 EDT
Maxim analyst Jason McCarthy downgraded Opexa Therapeutics to Hold from Buy on October 28, citing the failure of Tcelna, the company's T cell-based immunotherapy for the treatment of Secondary Progressive Multiple Sclerosis, in a phase 2b study. The analyst said he thinks it is unlikely that Tcelna can move forward in MS, though noted that there are other programs, such as NMO, that Opexa has that may be able to move forward.
News For OPXA From the Last 2 Days
There are no results for your query OPXA
